ULTRA LOW DOSE (<2 mg/day) vs ANY DOSE ‐ short term: Leaving the study early: any reason ‐ when compared with high dose ( greater than or equal to 10 mg)
ULTRA LOW DOSE (<2 mg/day) showed no clear difference in leaving the study early: Any reason ‐ when compared with high dose… compared with ANY DOSE ‐ short term (moderate certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
ULTRA LOW DOSE (<2 mg/day) vs ANY DOSE ‐ short term Leaving the study early: Any reason ‐ when compared with high dose (greater than or equal to 10 mg) · patients with schizophrenia ULTRA LOW DOSE (<2 mg/day) showed no clear difference in leaving the study early: Any reason ‐ when compared with high dose… compared with ANY DOSE ‐ short term (moderate certainty). Risperidone dose for schizophrenia (2009) · Cochrane Headline outcomes only | RR 0.94 [0.72, 1.23] | 1 study · 679 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.